Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine

Rheumatology

Volumn 40, Issue 9, 2001, Pages 1038-1043

  Coleiro, B ^a   Marshall, S E ^b   Denton, C P ^a   Howell, K ^a   Blann, A ^c   Welsh, K I ^b   Black, C M ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Fluoxetine; Nifedipine; Raynaud's phenomenon; Scleroderma; Serotonin reuptake inhibitor

Indexed keywords

FLUOXETINE; NIFEDIPINE; PADGEM PROTEIN; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; SELF REPORT; SIDE EFFECT; STATISTICAL ANALYSIS; THERMOGRAPHY; TREATMENT OUTCOME;

EID: 0034794451     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/40.9.1038     Document Type: Article

References (25)

1. Local asphyxia and symmetrical gangrene of the extremities
2. Raynaud's phenomenon
3. Pharmacotherapy of Raynaud's phenomenon
4. Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial
5. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon
6. Raynaud's disease, Raynaud's phenomenon, and serotonin
7. Serotonin and Raynaud's phenomenon
8. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5HT2) receptor
9. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis
10. Serotonin reuptake inhibitors in Raynaud's phenomenon
11. Case of fluoxetine-induced remission of Raynaud's phenomenon-A case report
12. The endothelium: Its role in scleroderma
13. von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis
14. von Willebrand factor: Increased levels are related to poor prognosis in systemic sclerosis and not to tissue autoantibodies
15. Adenosine nucleotides and serotonin stimulate von Willebrand factor release from cultured human endothelial cells
16. Raynaud's phenomenon: A proposal for classification
17. Nifedipine in Raynaud's phenomenon: Relationship between immediate, short term and long term effects
18. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis
19. Effects of low-dose nifedipine on a cold provocation test in patients with Raynaud's disease
20. Nifedipine in the treatment of idiopathic Raynaud's syndrome
21. Age, platelet serotonin kinetics and 5HT2-receptor blockade in essential hypertension
22. Serotonergic status in human blood
23. Determination of serotonin in whole blood, platelet-rich plasma, platelet-poor plasma, and plasma, ultrafiltrate
24. Fluoxetine: Clinical pharmacology and physiologic disposition
25. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder